ReutersA single dose of human papillomavirus (HPV) vaccine is enough to protect against cervical cancer, a World Health Organization group of experts said.
AstraZeneca said on March 24 the company’s drug Imfinzi, along with chemoradiotherapy, failed to achieve the main goal of improving survival in patients with locally advanced cervical cancer without the disease worsening.
Regeneron Pharmaceuticals and the company’s partner Sanofi voluntarily withdrew their application with the U.S. drug regulator for the expanded use of the anti-cancer drug Libtayo in patients with advanced cervical cancer.
Young women who were vaccinated against human papillomavirus (HPV) in their teens with an older GlaxoSmithKline product called Cervarix had up to an 87 percent lower risk of developing cervical cancer linked to the virus, a long-running English study found.
Germany’s Merck KGaA and Britain’s GlaxoSmithKline on Thursday ended their collaboration on the cancer treatment bintrafusp alfa, once seen as one of Merck’s most promising experimental drugs.
Genmab A/S and Seagen Inc. announced that the U.S. Food and Drug Administration granted accelerated approval to Tivdak (tisotumab vedotin-tftv), the first approved antibody-drug conjugate for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Oxford, U.K.-based Vaccitech reportedly filed confidentially in the United States for an initial public offering (IPO) on the Nasdaq.
Vaccinating nine in 10 girls under the age of 15 years against cervical cancer, and improved screening and treatment of women could reduce infections by 40% and save 5 million lives by 2050, the World Health Organization (WHO) said.
Routine medical tests critical for detecting and monitoring cancer and other conditions plummeted in the United States since mid-March, as the coronavirus spread and public officials urged residents to stay home, according to a new report by Komodo Health.
Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.